Debra Silberg
Direttore/Membro del Consiglio presso Ellodi Pharmaceuticals
Posizioni attive di Debra Silberg
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Ellodi Pharmaceuticals
 Ellodi Pharmaceuticals BiotechnologyHealth Technology Ellodi Pharmaceuticals engages in the provision of pharmaceutical services. It is dedicated to the clinical development of APT-1011, a novel therapy in Phase 3 development for the treatment of Eosinophilic Esophagitis (EoE) spun-out of Adare Pharmaceuticals (Adare). The company is headquartered in the United States. | Direttore/Membro del Consiglio | 27/02/2023 | - |
Storia della carriera di Debra Silberg
Precedenti posizioni note di Debra Silberg
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| FINCH THERAPEUTICS GROUP, INC. | Direttore Tecnico/Scientifico/R&S | 10/11/2021 | - |
| SHIRE | Corporate Officer/Principal | 01/04/2015 | - |
Formazione di Debra Silberg
| University of Michigan | Undergraduate Degree |
| D'Amore-Mckim School of Business | Doctorate Degree |
| The Wayne State University School of Medicine | Doctorate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 6 |
| Irlanda | 2 |
Posizioni
| Doctorate Degree | 2 |
| Corporate Officer/Principal | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
Settori
| Consumer Services | 4 |
| Health Technology | 3 |
| Health Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| FINCH THERAPEUTICS GROUP, INC. | Health Services |
| Aziende private | 2 |
|---|---|
Shire Plc
 Shire Plc Pharmaceuticals: MajorHealth Technology Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland. | Health Technology |
Ellodi Pharmaceuticals
Ellodi Pharmaceuticals BiotechnologyHealth Technology Ellodi Pharmaceuticals engages in the provision of pharmaceutical services. It is dedicated to the clinical development of APT-1011, a novel therapy in Phase 3 development for the treatment of Eosinophilic Esophagitis (EoE) spun-out of Adare Pharmaceuticals (Adare). The company is headquartered in the United States. | Health Technology |
- Borsa valori
- Insiders
- Debra Silberg
- Esperienza
